Pediatric Lyme Disease: Why Standard Protocols Fall Short

Pediatric Lyme disease treatment guidelines provide useful direction
Evidence is more limited when symptoms persist or become complex
Children require age-appropriate evaluation and careful monitoring

Your child cannot concentrate in school. They are exhausted by midafternoon. Joint pain keeps them off the soccer field. Although pediatric studies support antibiotic treatment for recognized manifestations of Lyme disease, physicians have much less pediatric-specific trial evidence to guide decisions when symptoms persist after treatment.

Children were not included in the major randomized antibiotic retreatment trials for persistent Lyme disease symptoms. Those studies primarily examined adults, leaving important questions about children and adolescents unanswered.

Children Aren’t Small Adults

Children’s immune systems, nervous systems, and metabolism change throughout childhood and adolescence. Their responses to infection, medication, and prolonged illness may differ from those of adults in ways that adult studies cannot fully capture.

When clinicians apply pediatric Lyme disease treatment guidelines, they rely on a combination of pediatric research, adult evidence, expert consensus, weight-based dosing, and clinical experience.

Pediatric studies have evaluated antibiotic treatment for recognized manifestations such as erythema migrans. However, the evidence becomes more limited when a child continues to experience fatigue, pain, cognitive difficulties, sleep disruption, or reduced physical function after initial treatment.

The American Academy of Pediatrics has published guidance summarizing pediatric recommendations from the 2020 Lyme disease guidelines. These recommendations provide a valuable starting point, particularly for early and well-defined manifestations of Lyme disease. [1]

However, no guideline can address every child’s presentation. Age, weight, developmental stage, medication tolerance, illness severity, coexisting conditions, and response to previous treatment may all influence clinical decisions.

What Parents May Notice First

Pediatric Lyme disease does not always begin with an obvious swollen joint or a clearly recognized erythema migrans rash. Parents may first notice fatigue, headaches, pain, irritability, difficulty concentrating, or declining participation in school and activities.

These symptoms are nonspecific and can have many possible causes. Fatigue may be interpreted as moodiness. Headaches may be blamed on screen time. Joint pain may be dismissed as growing pains. Changes in school performance may initially be attributed to stress, anxiety, inadequate sleep, or attention problems.

Studies describing children with neurologic Lyme disease have reported symptoms that included headaches, fatigue, behavioral changes, forgetfulness, and declining school performance. These findings do not mean that every child with cognitive or behavioral changes has Lyme disease, but they illustrate why a careful clinical evaluation matters. [2]

Delayed recognition can postpone appropriate evaluation and treatment. A physician should consider the child’s complete history, including tick exposure, geographic risk, objective findings, symptom progression, testing, and alternative diagnoses.

Treatment Can Affect More Than Physical Symptoms

Younger children may have difficulty describing pain, dizziness, cognitive changes, or medication side effects. Adolescents may minimize their symptoms because they do not want to miss school, sports, or time with friends.

Illness can also disrupt education, physical activity, sleep, friendships, and family life. These functional effects are rarely captured fully in adult clinical trials.

Parents can help by documenting changes in energy, sleep, pain, concentration, mood, school attendance, physical activity, and medication tolerance. A simple symptom record may help the physician identify improvement, deterioration, or patterns that are otherwise difficult to recognize during a brief appointment.

The Pediatric Lyme Research Gap

Pediatric antibiotic trials have examined treatment for early manifestations such as solitary erythema migrans. These studies provide evidence that children can be treated successfully with recommended antibiotics. [3,4]

A more recent study examining outcomes after pediatric Lyme disease found that most treated children experienced full symptom resolution within six months. A smaller group reported persistent symptoms that affected daily functioning. [5]

The evidence gap is therefore not the absence of all pediatric Lyme research. The greater limitation involves children with persistent, recurrent, neurologic, cognitive, or otherwise complex symptoms.

Important questions remain:

• What is the optimal approach when symptoms persist after recommended treatment?
• Do younger children and adolescents experience persistent symptoms differently?
• Which outcomes should pediatric Lyme disease studies measure?
• How should physicians assess changes in school performance, cognition, sleep, and physical function?
• Which medication risks and benefits differ by age or developmental stage?
• How should clinicians distinguish ongoing Lyme-related symptoms from another illness or a new diagnosis?

The major randomized trials of additional antibiotic treatment for persistent Lyme disease symptoms largely studied adults. Their findings and limitations continue to influence treatment recommendations, but they do not answer every question involving children. [6-8]

A fourth frequently cited study, the European PLEASE trial, compared longer-term antibiotic regimens in adults with persistent symptoms attributed to Lyme disease. Like the other major retreatment trials, it did not provide direct evidence for treating children. [9]

Future pediatric studies should measure more than symptom scores. School attendance, academic performance, cognition, sleep, physical activity, social participation, and family functioning are also meaningful treatment outcomes.

Why Clinical Judgment Still Matters

Clinical judgment does not mean disregarding evidence. It means applying the available evidence to an individual child while acknowledging what the research can and cannot establish.

Some clinicians follow standard treatment timelines closely. Others place greater emphasis on the child’s response, illness complexity, and functional recovery. Differences in care may reflect genuine uncertainty within the evidence rather than poor medical practice.

When a child does not improve as expected, the next step should not automatically be additional antibiotic treatment. A careful reassessment may include reviewing the original diagnosis, medication adherence, treatment response, possible adverse effects, tick exposure, possible co-infections, and alternative explanations for continuing symptoms.

Possible co-infections such as Babesia or Anaplasma should be considered when the exposure history, clinical presentation, and appropriate testing support that concern. They should not be presumed solely because symptoms persist.

What Children Need

Children with Lyme disease benefit from care tailored to their age, weight, developmental stage, symptoms, and clinical response. Careful monitoring can help clinicians recognize improvement, detect complications, and determine whether additional evaluation is needed.

Recovery may not be reflected by one symptom alone. Small functional changes can be meaningful, including improved concentration, steadier school attendance, better sleep, less pain, or a gradual return of energy and physical activity.

Children may benefit from collaboration among pediatricians, family physicians, infectious disease specialists, neurologists, rheumatologists, cardiologists, mental health professionals, and clinicians experienced in tick-borne illness, depending on the presentation.

If symptoms persist, worsen, or remain unexplained, parents should discuss these changes with the treating physician. A second opinion may be appropriate when important concerns remain unresolved.

Questions Parents Should Ask

• How has this treatment plan been adapted for my child’s age, weight, and development?
• Which findings support the Lyme disease diagnosis?
• What symptoms or medication side effects should I monitor?
• How will we determine whether treatment is working?
• What should we do if symptoms do not improve as expected?
• Should another diagnosis or complication be considered?
• Does my child’s presentation warrant evaluation for a tick-borne co-infection?
• How should we monitor school attendance, concentration, sleep, and physical function?

These questions can help ensure that treatment decisions reflect both current pediatric Lyme disease treatment guidelines and the individual child’s needs.

Working Within Current Guidelines

The American Academy of Pediatrics and the joint guidelines from the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology provide recommendations for treating pediatric Lyme disease.

These recommendations are particularly useful for recognized manifestations such as erythema migrans, Lyme arthritis, facial nerve palsy, Lyme carditis, and other defined presentations. Many children recover well when Lyme disease is recognized and treated appropriately.

The 2020 IDSA/AAN/ACR guideline recommends against additional antibiotic treatment for persistent nonspecific symptoms when there is no objective evidence of reinfection or treatment failure. The ILADS guidelines emphasize individualized clinical judgment and shared decision-making when patients remain ill after initial treatment.

I served as first author of the ILADS guidelines published in 2004 and 2014. The 2014 guidelines recommend considering illness severity, previous treatment response, alternative diagnoses, treatment risks, and the patient’s values and circumstances. [10,11]

These different recommendations do not eliminate the underlying research limitation: randomized pediatric retreatment trials have not established how children with persistent symptoms respond to additional antibiotic treatment.

However, guidelines also reflect the boundaries of the available evidence. When symptoms persist, the diagnosis is uncertain, or the clinical presentation is unusually complex, physicians must combine guideline recommendations with careful reassessment and individualized clinical judgment.

The Bottom Line

Pediatric Lyme disease treatment is not based entirely on adult research. Studies involving children support antibiotic treatment for several recognized manifestations of the infection.

The more important evidence gap concerns children who continue to experience fatigue, pain, cognitive difficulties, sleep disruption, or impaired daily function after initial treatment. The major randomized retreatment trials that inform this area largely enrolled adults.

Both undertreatment and unnecessary treatment carry risks. Decisions should account for the child’s diagnosis, illness severity, previous response, medication risks, and functional impairment.

Many children recover well with appropriate care. When recovery is slower or more complicated, careful monitoring, open communication, reassessment of the diagnosis, and thoughtful clinical judgment become especially important.

Frequently Asked Questions

Were children excluded from all Lyme disease treatment studies?

No. Pediatric studies have evaluated antibiotic treatment for recognized manifestations such as erythema migrans. However, children were not included in the major randomized antibiotic retreatment trials for persistent Lyme disease symptoms.

Are pediatric Lyme disease treatment guidelines unsafe?

No. Current pediatric Lyme disease treatment guidelines provide evidence-based recommendations for recognized manifestations of the illness, and many children recover well with recommended care. The limitation is that considerably less evidence is available for children with persistent or complex symptoms.

How can Lyme disease symptoms appear in children?

Children may develop recognized manifestations such as erythema migrans, facial nerve palsy, arthritis, carditis, or neurologic symptoms. Parents may also report fatigue, headaches, pain, concentration problems, or changes in daily function. Because these symptoms can have many causes, a comprehensive medical evaluation is important.

What should parents do if symptoms persist after treatment?

Parents should tell the child’s physician which symptoms remain, how they affect daily function, and whether any new symptoms have appeared. The physician may reassess the original diagnosis, review treatment response, consider medication effects, evaluate for another condition, or determine whether additional tick-borne disease evaluation is appropriate.

Should every child with persistent symptoms be tested for co-infections?

No. Evaluation for Babesia, Anaplasma, or another tick-borne infection should be guided by the child’s exposure history, symptoms, examination, and appropriate diagnostic testing rather than persistent symptoms alone.

How can parents find a physician experienced in pediatric Lyme disease?

Begin with the child’s pediatrician or family physician. When additional expertise is needed, referrals may include pediatric infectious disease, neurology, rheumatology, cardiology, or a clinician experienced in evaluating children with tick-borne diseases.

Clinical Takeaway

Pediatric Lyme disease treatment guidelines offer useful recommendations for recognized manifestations, and many children recover well with appropriate care. Pediatric research exists, but evidence remains limited for children with persistent, recurrent, cognitive, neurologic, or function-limiting symptoms.

When recovery does not proceed as expected, physicians should reassess the diagnosis, review the child’s treatment response, consider other possible explanations, and monitor both symptoms and daily function.

Children with Lyme disease benefit most from evidence-informed care that recognizes both established guidelines and the limits of pediatric-specific research.

Related Articles

Lyme symptoms in adolescents can be missed
Lyme disease in adolescents
Pediatric Lyme disease symptoms and diagnosis

References

1. Meissner HC, Steere AC. Management of pediatric Lyme disease: Updates from 2020 Lyme guidelines. Pediatrics. 2022;149(3):e2021054980.
2. Bloom BJ, Wyckoff PM, Meissner HC, Steere AC. Neurocognitive abnormalities in children after classic manifestations of Lyme disease. Pediatr Infect Dis J. 1998;17(3):189–196.
3. Arnež M, Radšel-Medvešček A, Pleterski-Rigler D, Ružić-Sabljić E, Strle F. Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wien Klin Wochenschr. 1999;111(22–23):916–922.
4. Nižič T, Velikanje E, Ružić-Sabljić E, Arnež M. Solitary erythema migrans in children: Comparison of treatment with clarithromycin and amoxicillin. Wien Klin Wochenschr. 2012;124(13–14):427–433.
5. Monaghan M, Norman S, Gierdalski M, Marques A, Bost JE, DeBiasi RL. Pediatric Lyme disease: Systematic assessment of post-treatment symptoms and quality of life. Pediatr Res. 2024;95(1):174–181.
6. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345(2):85–92.
7. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): A randomized double-masked clinical trial. Neurology. 2003;60(12):1923–1930.
8. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70(13):992–1003.
9. Berende A, ter Hofstede HJM, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374(13):1209–1220.
10. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: The clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014;12(9):1103–1135.
11. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America, American Academy of Neurology, and American College of Rheumatology: 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021;72(1):e1–e48.

This article is for informational purposes only and does not replace evaluation or treatment by a qualified healthcare professional.

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention